The FDA extended the duration of use of Nexplanon for pregnancy prevention in women of reproductive potential for up to 5 years.
Zacks Investment Research on MSN
Organon secures FDA approval extending NEXPLANON use to five years
Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of ...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results